New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 21, 2014
08:18 EDTRGLSRegulus Therapeutics granted orphan drug designation for RG-012 by FDA
Regulus Therapeutics announced that the FDA has granted orphan drug designation to RG-012, a single stranded, chemically modified oligonucleotide that binds to and inhibits the function of microRNA-21, as a therapeutic for the treatment of Alport syndrome, a life-threatening genetic kidney disease with no approved therapy. In the near term, Regulus expects to initiate a natural history of disease study to gather further information about the progression of Alport syndrome and to inform future clinical development plans of RG-012, a key program under Regulus' 'Clinical Map Initiative'.
News For RGLS From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 24, 2014
10:00 EDTRGLSOn The Fly: Analyst Initiation Summary
Subscribe for More Information
06:00 EDTRGLSRegulus Therapeutics initiated with a Buy at Deutsche Bank
Subscribe for More Information
November 19, 2014
08:59 EDTRGLSRegulus Therapeutics data positive, says Wedbush
Subscribe for More Information
November 16, 2014
14:44 EDTRGLSRegulus, Sanofi present new data enhancing the preclinical profile of RG-012
Subscribe for More Information
November 13, 2014
10:27 EDTRGLSHigh option volume stocks
Subscribe for More Information
07:54 EDTRGLSRegulus Therapeutics 2M share Block Trade priced at $18.25
Morgan Stanley acted as sole book running manager for the offering.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use